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Abstract With the adoption of combination antiretroviral
therapy (ART), most HIV-infected individuals in care are
on five or more medications and at risk of harm from
polypharmacy, a risk that likely increases with number of
medications, age, and physiologic frailty. Established
harms of polypharmacy include decreased medication
adherence and increased serious adverse drug events,
including organ system injury, hospitalization, geriatric
syndromes (falls, fractures, and cognitive decline) and
mortality. The literature on polypharmacy among those
with HIV infection is limited, and the literature on poly-
pharmacy among non-HIV patients requires adaptation to
the special issues facing those on chronic ART. First, those
aging with HIV infection often initiate ART in their 3rd or
4th decade of life and are expected to remain on ART for
the rest of their lives. Second, those with HIV may be at
higher risk for age-associated comorbid disease, further
increasing their risk of polypharmacy. Third, those with
HIV may have an enhanced susceptibility to harm from
polypharmacy due to decreased organ system reserve,
chronic inflammation, and ongoing immune dysfunction.
Finally, because ART is life-extending, nonadherence to
ART is particularly concerning. After reviewing the rele-
vant literature, we propose an adapted framework with
which to address polypharmacy among those on lifelong
ART and suggest areas for future work.
1 The Drug Treatment Paradox: What is Different
Among those Aging with HIV?
Physicians and their aging patients face a drug treatment
paradox [1]. Aging individuals inevitably develop multiple
health conditions (multimorbidity), and disease-specific
guidelines recommend one or more additional medications
for each diagnosis [2–6]. Evidence supporting these rec-
ommendations is of variable strength and was obtained
from younger patients free of competing health conditions
and less susceptible to medication toxicity [4, 5]. Con-
versely, older multimorbid patients may be more likely to
benefit from certain organ-sparing treatments.
This paradox is particularly challenging for those aging
with HIV infection, in whom the effectiveness of combi-
nation antiretroviral therapy (ART) is undeniable, guide-
lines recommend aggressive screening and treatment for a
host of other health conditions (many of which may be
more common among those with HIV), higher rates of
organ system injury mean that they are particularly sus-
ceptible to treatment toxicity, and nonadherence to ART is
much more concerning than nonadherence to most other
medications.
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Polypharmacy, commonly defined as being on C5
medications, is a growing problem in healthcare. It is the
strongest predictor of serious adverse drug events (ADE)
and drug–drug interactions [2, 7, 8]. While polypharmacy
is a pressing issue in primary care, it may be an even
greater concern among those aging with HIV infection, in
whom combination ART has simultaneously increased
survival [9–11] and the lifelong burden of medication [12,
13]. Several excellent reviews of the general issues of
polypharmacy [14–16] have been published, and the
Cochrane Collaboration recently conducted a structured
review of interventions to improve the appropriate use of
polypharmacy for older people [1]. General issues sur-
rounding older, HIV-infected patients, focusing on those
aged 50 and older, have also been delineated [17]. How-
ever, prior work has not addressed specific management
issues surrounding polypharmacy among those aging with
HIV infection.
Those aging with HIV have several somewhat unique
management issues. First, polypharmacy is often ‘‘pre-
mature’’ in those with HIV. Since ART typically requires
the use of at least three different antiretrovirals, many
people with HIV experience polypharmacy the minute they
start ART. For example, data from the North American
AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) demonstrate that that while two-thirds of
patients who are newly eligible for treatment are in their
30s and 40s, 17 % are younger than 30 [18]. Thus, their
total time of exposure to polypharmacy is extended com-
pared to the general population, which more typically
begins lifelong therapy for chronic diseases such as
hypertension, cardiovascular disease, or diabetes in their
5th, 6th, or 7th decade. Second, those aging with HIV are at
higher risk for many age-associated conditions that may be
driven in part by HIV infection and ART toxicity (e.g.,
hyperlipidemia, atherosclerosis, and osteoporosis) [17, 19–
21]. Additionally, current Department of Health and
Human Services (DHHS) guidelines recommend that pri-
mary care guidelines be applied equally to those aging with
HIV [22]. Given the lower thresholds for the treatment of
conditions such as hypertension, hyperlipidemia, and dia-
betes that have been adopted over the last decade, the
application of these guidelines to those aging with HIV will
almost inevitably lead to increasing levels of polypharmacy
[23]. While evidence supporting ART for HIV infection is
overwhelming, the strength of evidence for other routine
screening and treatment practices is variable and based on
studies in demographically and behaviorally distinct unin-
fected individuals.
Third, those with HIV infection may have an enhanced
susceptibility to harm from polypharmacy due to decreased
organ system reserve, chronic inflammation, and ongoing
immune dysfunction [20, 21]. Due to the increased prev-
alence of both liver [24] and renal disease [25–27] among
older, HIV-infected patients, they may have altered phar-
macodynamics and be more vulnerable to injury from both
commonly used non-HIV medications [28], as well as
cART [29, 30]. Fourth, polypharmacy is associated with
poorer adherence, so adding medication to address other
problems may diminish the life-preserving effectiveness of
ART. We consider these issues as we review the general
and HIV-specific literature relevant to polypharmacy, and
suggest how existing interventions might be adapted to
those aging with HIV.
2 Methods
We performed a comprehensive review of the literature,
searching the following databases for relevant studies:
MEDLINE (OvidSP 1948 to September 2012); Embase
(OvidSP 1974 to September 2012), and CENTRAL
(Cochrane Library, September 2012). The search strategies
used a combination of controlled vocabulary terms and text
words to capture the concepts of polypharmacy and spe-
cific conditions/issues [drug interactions, medication
errors, inappropriate prescribing, falls, hospitalization,
adverse drug reaction, mortality, quality of life, organ
injury (e.g., liver failure, renal insufficiency, etc.), and
activities of daily living], and were limited to English
language manuscripts and to subjects 45 years or older. We
used this cutoff given our interest in focusing on older
HIV-infected patients, commonly defined as 50 years and
older [17]. The reference lists of included papers were
hand-searched. Together, these papers provided the foun-
dation for our discussion on polypharmacy. We comple-
mented this with targeted searches that were performed as
needed, including searches for studies focused on HIV-
infected populations.
3 What is Polypharmacy?
A range of definitions have been applied to the term pol-
ypharmacy, including the use of at least one unnecessary
medication and different thresholds for the number of
medications in a patient’s regimen [7, 8, 31]. There is a
clear dose–response association with harms of polyphar-
macy, so that those who are on 5–6 medications are at
lower risk than those on 7–8 or [9 medications [32–34].
Consistent with others [8, 35], we prefer to define poly-
pharmacy specifically as the use of 5 or more medications
in a medication regimen, since this threshold has been
consistently associated with important negative health
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outcomes [36] and is supported by empiric work [37].
Specifically, Gnjidic and colleagues explored the best
cutoff for defining polypharmacy based on associations
with health outcomes among a community sample of older
men. They found that the number of medications was 6.5 to
identify risk of frailty, 5.5 for disability, 4.5 for mortality,
and 4.5 for falls, supporting the use of 5 or more medica-
tions as a clinically meaningful definition of polypharmacy
[37].
4 How Common is the Problem of Polypharmacy
in HIV?
Polypharmacy among those in care for HIV infection is
common. One study, which examined data from a Cana-
dian cohort from 1990 to 2010, found that the total daily
pill burden (TDPB) decreased over time; this was attrib-
uted to improvements in ART. Yet, in 2010, 22 % of
patients took 10 or more pills per day (mean TDPB
6.7 ± 5.8), 51 % of which were ART. Further, older
patients (defined as older than 45 years old) took, on
average, 3 pills more per day than younger patients
(defined as 45 years old or younger) (7.6 vs. 4.7 pills),
which was generally related to their greater need for non-
ART medications [13]. Similarly, recent data from the
Swiss HIV Cohort demonstrate that among those 65 years
and older, 14 % received medications from 4 or more
classes of non-HIV medications, where lipid-lowering
agents were the most commonly prescribed non-ART
medication [12]. These data are consistent with findings
from the Veterans Aging Cohort Study (VACS), where the
average number of daily long-term medications increased
with age (Fig. 1) (unpublished data). Further, among those
50 years and older, 55 % were on 5 or more daily
medications.
Because these studies report only prescription medica-
tion, they likely underestimate the prevalence of poly-
pharmacy [13, 38–44]. Among all the medications that 104
HIV-infected patients interviewed in Ontario reported that
they used, 18 % were ART, 22 % were non-ART pre-
scriptions, 25 % were over-the-counter, 22 % were com-
plementary and alternative, and 13 % represented
nonmedical use [39]. Of note, 17 % of HIV-infected
patients experience at least one or more ADE attributable
to an over-the-counter medication [44]. Further, patient
self-medication is common [2], especially among HIV-
infected patients [39, 45, 46]. Even when excluding drugs
used for nonmedical reasons, patients reported an average
number of drugs of 14 ± 8, compared to 8 ± 5 docu-
mented in the medical chart [39]. A systematic review
found that there is variability in whether patients report
their use of complementary and alternative medicine to
their health care providers, with rates ranging from 38 to
90 % [45].
5 What is the Most Important Treatment in HIV?
Evidence for the efficacy of ART is overwhelming [9, 47].
While very effective, the use of ART in older HIV-infected
patients may be associated with more toxicity than it is
among younger individuals. First, there are limited data
evaluating the safety and efficacy of ART in older popu-
lations and the impact of multiple medications. Random-
ized controlled trials generally include younger, healthier
patients, excluding older patients with comorbidity [48–
50]. Despite their potential for altered efficacy, metabo-
lism, ADE, and drug interactions in older patients, there is
a paucity of data to inform the choice of antiretroviral
agents in this population [17, 22, 51, 52]. This applies to
recently approved medications as well [48–50].
Second, ADE are common with ART [53], and older
patients are more likely to experience ADE, leading to
treatment discontinuation [29]. Third, there are evolving
data on the potential for harm with the long-term use of
ART, with specific implications for older patients. For
instance, there is evidence of increased risk of fracture [54]
and renal disease [55–57] with the long-term use of ten-
ofovir, a component of all of the currently recommended
first-line regimens for treatment-naı¨ve individuals [22].
While these data highlight the need for evidence assessing
the long-term effects of ART and their safety in older
populations, they do not undermine the fact that ART is
highly effective at preventing AIDS-defining and non-
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Fig. 1 Veterans Aging Cohort Study: median number of daily long-
term medications by HIV status and age. Thin black bar indicates the
corresponding 95 % confidence interval
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prolonging survival. The question is not whether or not
older individuals should be treated with ART, but which
antiretrovirals should be selected and how commonly
should they be monitored for toxicity.
6 Polypharmacy and Harms
6.1 Nonadherence
Polypharmacy is strongly associated with nonadherence in
the general population [7, 58, 59]. Marcum and Gellad
propose that, among older patients, this may be related to a
dynamic process involving patient, health system, and
provider factors. A recent systematic review found that
nonadherence was associated with polypharmacy when
focusing on the results of higher-quality studies [58, 59].
Nonadherence to ART is especially concerning, since it is
associated with increased risk of hospitalization and mor-
tality [60, 61].
Nevertheless, the effects of polypharmacy on ART and
non-ART adherence are only beginning to be examined.
An analysis of healthcare and pharmacy claims data
including 3,057 patients found a relationship between
increasing number of comorbidities and discontinuation of
ART. Patients with 1, 2, and 3 or more comorbidities had a
6 % (p = 0.528), 28 % (p = 0.014), and 31 % (p = 0.02),
respectively, higher risk of ART discontinuation compared
with patients with no comorbidities [62]. While multiple
factors may be at play, polypharmacy may contribute to
these findings.
Notably, older HIV-infected patients are at increased
risk for neurocognitive dysfunction, substance-use disor-
ders, food insecurity, and limited social support compared
with older uninfected patients [17, 19, 63–67]; these factors
negatively impact adherence [40, 61, 68, 69]. Whether
these relationships are exacerbated by polypharmacy and
their differential effects on ART and non-ART adherence
remains to be determined.
6.2 Adverse Drug Events
While yet to be studied among those aging with HIV, there
is strong evidence that polypharmacy increases the risk of
ADE in the general population. A prospective study of
individuals receiving outpatient care and newly initiating a
medication found that the number of medications that a
patient took was the only variable associated with the
occurrence of an ADE (p \ 0.001) [33]. Moreover, with
each additional medication, the mean number of ADE per
patient increased by 10 % [33]. While this study included a
range of severity of ADE, these findings are consistent with
studies that have assessed serious events. After adjusting
for demographics, health status, and access-to-care factors,
number of medications was found to be the only factor
associated with ADE-related hospitalization. Risk
increased with increasing threshold for number of medi-
cations: adjusted odds ratios [AOR] for 5–8 and C9 med-
ications were 2.85 [1.03, 7.85] and 3.90 [1.43, 10.61],
respectively [35].
6.3 Geriatric Syndromes: Falls, Fractures,
and Dementia
Geriatric syndromes including falls, fragility fractures,
and dementia are more likely in the setting of polyphar-
macy and increasingly relevant to HIV care as patients
age in the era of combination ART [7]. While specific
classes of medications, including antidepressants, analge-
sics, benzodiazepines, and antihypertensives, have been
associated with increased risk of falling [70], polyphar-
macy is independently associated with falls and fall-
related injuries among the general population [71, 72].
Taken together, polypharmacy is one of the strongest
predictors of fall risk [73]. Based on the results of 10
studies, a meta-analysis found that, for each additional
medication, there was a 5 % increase in fall risk
(AOR = 1.05 [95 % CI 1.01, 1.09]) among community-
dwelling older uninfected adults [74].
Further, even more than decreased bone mineral density,
falls are the major cause of fragility fractures [75]. Results
from one cohort study of HIV-infected patients with a
median age of 36 years found that, among patients who
experienced a fracture, 81 % of them sustained a fall as an
immediate cause of the fracture [76]. Since low bone
mineral density [76–78] means that HIV-infected patients
are at increased susceptibility for fragility fractures, falls
are of particular concern in this population. A study of 359
HIV-infected patients aged 45 to 65 years old on ART for
at least 6 months with 1 undetectable plasma HIV-1 RNA
viral load and no plasma HIV-1 RNA [ 200 copies per
milliliter in the prior 6 months demonstrated that each
additional prescribed medication was associated with an
incremental increase of 1.4 in the odds of falls (95 % CI
1.3 to 1.6, p \ 0.001) [79].
Risk of dementia and delirium is also increased in
polypharmacy [7]. A prospective cohort study of 294
uninfected older persons found that individuals receiving
10 or more drugs, demonstrated decreased cognitive
function over a 3-year time period compared to those on
0–5 medications [32]. HIV-associated neurocognitive
disorder (HAND) can be an asymptomatic condition [80].
While the literature demonstrate that polypharmacy may
contribute to symptomatic cognitive dysfunction [7, 32],
patients with HAND may be more susceptible to these
effects.
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6.4 Mortality
Of all the harms associated with polypharmacy, most
notable is its association with mortality, even after
adjustment for disease burden [34, 36, 81]. Based on a
population-based study, Richardson and colleagues found
that people aged 65 years and older in the general popu-
lation with polypharmacy (defined as 5 or more medica-
tions) had a greater risk of mortality (adjusted HR 1.42
[95 % CI 1.28, 1.58] and 1.30 [95 % CI 1.19, 1.41] for men
and women, respectively) over the 18-year follow-up per-
iod. These risks were greatest, however, in the short term
(2 years) for both men (adjusted HR 1.94 [95 % CI 1.59,
2.37]) and women (adjusted HR 1.88 [95 % CI 1.56, 2.26])
[36].
A major methodologic challenge in determining whether
polypharmacy has an independent association with mor-
tality is its strong association with multimorbidity, which
is, in itself, a major driver of mortality risk. One approach
to this problem might be to adjust for overall risk of
mortality using a validated risk index such as the VACS
Index [82–85]. Nevertheless, while it remains to be deter-
mined whether polypharmacy is a risk factor for mortality
or an additional consequence of multimorbidity among the
general population and specifically HIV-infected patients,
those with polypharmacy likely deserve special care.
6.5 Over- and Underprescribing
Polypharmacy is linked to poorer medication prescribing
quality, including both over- (e.g., potentially inappropriate
medications) and underprescribing. Here, potentially
inappropriate medications refers to ‘‘medications [that]
have no clear evidence-based indication, carry a substan-
tially higher risk of adverse side-effects or [are] not cost-
effective (e.g. over prescribing)’’ [86]. Underprescribing
refers to the lack of prescription of a potentially effective
medication [87]. As the patient’s problem list and number
of medications expands, the provider’s ability to pay
attention to each condition and its treatment is reduced [6].
Similarly, increased number of medications is associ-
ated with an increased risk of exposure to harmful medi-
cations. An analysis of data from all VA outpatient clinics
focusing on individuals older than 65 years old found that
increased number of medications was associated with
exposure to any high-risk medication (OR = 1.13 [99 %
CI 1.12, 1.13]). Increased number of medications was also
associated with exposure to specific high-risk medications,
including antihistamines (OR = 1.12 [99 % CI 1.11,
1.12]), opioids (OR = 1.10 [99 % CI 1.09, 1.10]), psy-
chotropics (OR = 1.12 [99 % CI 1.12, 1.13]), and skeletal
muscle relaxants (OR = 1.10 [99 % CI 1.10, 1.10]) [88].
These findings are consistent with other studies [89].
Literature on the impact of polypharmacy on the underuse
of clinically indicated medications is mixed, as underuse
may occur regardless of the number of prescribed medi-
cations, but it most commonly identifies the underuse of
cardiovascular medications [2, 89].
To date, studies of prescribing practices to HIV-infected
patients have focused on quality of HIV care [90, 91], but
have not applied validated tools to assess for inappropriate
medication use. However, there are growing data on under-
and overprescribing among HIV-infected populations.
Errors involve the prescribing of both ART and ART/non-
ART combinations [92–94]. A review of claims data from
2005, including over 12,000 patients, found that simvastatin
was inappropriately co-prescribed with a protease inhibitor
to 0.4 % of patients, while atazanavir and tenofovir were
prescribed together without the recommended ritonavir
booster to 5.3 % of patients [94]. In addition, data on the
prescribing practices for individual classes of medica-
tions—including opioid analgesics [95–99]—are mounting,
with caution advised regarding prescribing practices [98].
As seen in HIV-uninfected patients [89], the underuse of
medications to decrease risk of cardiovascular disease
seems to occur regularly in HIV-infected patients. Freiberg
and colleagues found that the prevalence of lipid-lowering
medication among HIV-infected patients who met the
National Cholesterol Education Program/Adult Treatment
Panel III criteria for therapy was 39 %, compared with
62 % for uninfected patients (p \ 0.01). In multivariable
analysis, HIV-infected patients were almost 60 % less
likely than uninfected patients to receive indicated lipid-
lowering therapy (adjusted OR = 0.43 [95 % CI 0.28,
0.67]) [100]. Aspirin for primary prevention of cardiovas-
cular disease is also underprescribed to HIV-infected
patients; in one study, only one in five patients who qual-
ified for aspirin received it [101].
7 Factors Contributing to Polypharmacy’s Harms
7.1 Pre-existing Organ System Injury
The concept of physiologic frailty is important when con-
sidering risks from polypharmacy, and it is an established
concept in geriatrics [17]. Those who have pre-existing
physiologic injury are likely at increased risk of adverse
effects of treatment. What is not well established is how to
measure this concept. Since the VACS Index is predictive
of all-cause mortality, MICU admission, hospitalization,
fragility fractures, functional performance, and cognitive
function, and is correlated with biomarkers of chronic
inflammation, it may offer a means of summarizing phys-
iologic frailty among those with HIV infection [82–85,
102–105].
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7.2 Drug–Drug Interactions
The number of medicines prescribed predicts the number
of drug interactions likely to occur [1, 106]. HIV-infected
patients on ART are likely to be especially susceptible to
drug–drug interactions when receiving multiple medica-
tions [40, 41, 43, 107]. Protease inhibitors, non-nucleoside
reverse transcriptase inhibitors, the integrase inhibitor/
booster combination elvitegravir/cobicistat, and the CCR5
inhibitor maraviroc are all metabolized by the cytochrome
P450 (CYP) system and may function as both CYP
inhibitors and inducers, leading to complex and potentially
poorly predictable drug–drug interactions [22, 108]. In
addition, raltegravir is a substrate of uridine diphosphate
glucuronosyltransferase A1, an enzyme involved in the
conjugation of many medications—the understanding of
which is still evolving [108]. Guidelines recommend
avoiding the co-administration of a variety of medications
in the setting of ART, such as combinations of simvastatin
and protease inhibitors and proton pump inhibitors in the
setting of atazanavir or rilpivirine [22].
Not surprisingly, HIV-infected patients—especially
those who are older—are at high risk of drug–drug inter-
actions. Data from the Swiss HIV Cohort found that older
patients were more likely to receive at least one non-ART
medication than younger patients are (82 % vs. 61 %,
p \ 0.001), and they had more frequent potential drug–
drug interactions (51 % vs. 35 %, p \ 0.001) [43]. This
extends to prescription medications, over-the-counter
medications and herbal supplements [43, 44, 109]. Careful
attention to such potential drug–drug interactions [22, 40]
is necessary to minimize potential drug–drug interactions
[108]. Useful resources for ARV–drug interaction data
include the University of California HIV Insite website
(http://hivinsite.ucsf.edu/) and the University of Toronto
Immunodeficiency Clinic website (http://www.hivclinic.
ca/main/drugs_home.html). Of note, current data on drug–
drug interactions are generally based on healthy volunteers
[108]; there is less knowledge of the implications for older,
HIV-infected patients. Given the high prevalence of hep-
atitis C virus (HCV) coinfection and liver fibrosis among
HIV-infected patients [24, 30, 110] and the associated
implications for the pharmacodynamics and safety of both
ART and commonly used medications, providers should be
especially vigilant in checking for drug–drug interactions
among those aging with HIV.
7.3 Substance Use
Prolonged multisubstance use (including alcohol, tobacco,
non-medical use of controlled medications, and non-pre-
scription psychoactive drugs) is common among those
aging with HIV [46, 111] and likely plays a ‘‘silent’’ role in
adverse consequences of polypharmacy. Alcohol and drug
use, including opioids, cocaine, and methamphetamines,
have a major dose–response influence on medication
adherence and interactions with commonly prescribed
medications [68, 112–115]. Alcohol and tobacco can
influence drug clearance and activity levels directly and
through effects on liver and kidney function, with impor-
tant clinical impacts [116–119]. Use of controlled medi-
cations other than how they were prescribed or solely for
the effect they provide (non-medical use) can result in
over-sedation, overdose and death [120–122]. Non-medical
use of controlled medications, use of alcohol or illicit drugs
can result in serious unanticipated interactions with pre-
scribed drugs [123]. For instance, the metabolism of delta-
9-tetrahydrocannabinol, the active agent in marijuana—the
most commonly used illicit drug in the United States—is
thought to occur through CYP2C9, and is impacted by
selective serotonin reuptake inhibitors and tricyclic anti-
depressants [123]. Cocaine is a vasoactive compound that
can cause coronary ischemia.
7.4 Co-formulation
While co-formulated therapies can be beneficial for mini-
mizing dosing errors and improving medication adherence
through a reduced pill burden, caution should be exercised
among older individuals. For example, tenofovir disoproxil
fumarate has been coformulated with different antiretro-
viral agents, including emtricitabine as Truvada; emtri-
citabine and efavirenz as Atripla; emtricitabine and
rilpivirine as Complera; and emtricitabine and elvitegra-
vir/cobicistat as StribildTM. These co-formulated prepara-
tions can be problematic when one component is
contraindicated. For instance, tenofovir requires dose
adjustment in patients with renal insufficiency [22], which
is often missed [124]. Co-formulation can also be a prob-
lem in pain medication in which acetaminophen is often
co-formulated with opioid analgesics. This can lead to the
inadvertent prescribing of liver toxic medication to those
with documented liver injury [125].
7.5 Silos of Care
Continuity and integration of care has been identified as a
protective factor for minimizing polypharmacy, and silos
of care are a risk factor for polypharmacy [2]. Though less
true among older patients, HIV-infected patients often have
incomplete retention in care [126, 127], which may con-
tribute to polypharmacy. In addition, patients may be
co-managed by both HIV providers and generalists
[128–130], which may contribute to their risk of poly-
pharmacy and its consequences [131]. HIV-infected
patients receiving specialty psychiatric or addiction
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treatment often need to see multiple providers. Hospital-
ization often interrupts care continuity and contributes to
polypharmacy in the general population [2]. Hospitalization
occurs more frequently among those with HIV [132], and
represents a high-risk time for medication errors [133–135].
Another concern among those with HIV infection on ART
is that many routine issues are more familiar in primary
clinics but are likely strongly influenced by HIV and its
treatment. Data from VACS found that providers in Infec-
tious Disease Clinics were less comfortable with managing
comorbid diseases such as diabetes and hypertension than
physicians practicing in General Medicine Clinics [136].
Where care is best provided and how to ensure continuity
remains a major problem, though multidisciplinary team-
based approaches are likely to be essential [137, 138].
8 Interventions to Promote Safe, Effective, Prioritized
Prescribing
The evidence base for interventions to mitigate harms and
maximize benefit among those at risk from polypharmacy is
limited. A recent systematic review by the Cochrane Col-
laboration to identify interventions to improve medication
prescribing for older people found, based on the results of 10
studies, that ‘‘it is unclear if interventions to improve
appropriate polypharmacy, such as pharmaceutical care,
resulted in a clinically significant improvement; however,
they appear beneficial in terms of reducing inappropriate
prescribing and medication-related problems’’ [1].
While it is apparent that the optimal strategy for pro-
moting safe prescribing is evolving, we draw from previ-
ously proposed frameworks and our own research and
clinical experience to suggest an initial approach adapted to
the special needs of those aging with HIV infection
(Fig. 2). These recommendations are influenced by the
criteria developed by Gallagher, Beers and others [139–
142], the conceptual framework proposed by Scott et al.
[16], the Cochrane review [1], and work including the use
of a Clinical Decision Support intervention [143], assess-
ments of symptom burden [144], and considerations for
applying clinical care guidelines [145], including cancer
screening in HIV [146]. We note that these recommenda-
tions require time and effort and therefore encourage
research on workload distribution, efficacy, implementa-
tion, and cost–benefit, given the fundamental value of
medication safety. This represents a proposed framework
that still requires further evaluation.
8.1 Medication Reconciliation
This is an essential but time-consuming step. List all
medications, the level of adherence, and associated symp-
toms. Start with a complete dispensing history from the
Fig. 2 Optimizing medication
prescribing. ART antiretroviral
therapy, VACS Veterans Aging
Cohort Study
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pharmacy and compare to the electronic medical record or
paper chart and ask the patient to bring in all medications
(‘‘brown bag’’) [14]. It is essential that medication recon-
ciliation includes questioning regarding supplements and
over-the-counter medications [15] and an honest discussion
with the patient about their level of adherence and sense of
associated symptoms [144]. This process should be per-
formed at least annually [14] and updated whenever med-
ications are changed. All medications need to be verified
for drug name, dose, frequency, and last fill date. Thera-
peutic duplication and continued indication should be
evaluated prior to each renewal. If electronic fill/refill data
is available, medication possession ratios can provide an
unbiased estimate of adherence [147]. Those who live with
the patient might also be asked to verify the medications,
adherence, and associated symptoms. The process of
medication reconciliation might be facilitated by a clinical
pharmacist working in conjunction with the clinic or pri-
mary care provider. If possible, patients should utilize one
pharmacy, as it will both facilitate medication reconcilia-
tion and help avoid risks from polypharmacy [17]. The
efficiency of medication reconciliation may be improved
through contact with the patient prior to the clinical
encounter. For example, most primary care VA clinics ask
the patient to review their list of current VA and non-VA
medications prior to the clinical encounter and to discuss
any discrepancies with their provider.
8.2 Assess Substance Use
Substance use, including alcohol and marijuana, is com-
mon among those with HIV infection, and influences risk
of polypharmacy, likelihood of nonadherence, and sus-
ceptibility to adverse drug reactions (Table 1) [22, 114,
115, 123, 148–162]. This assessment can be done concisely
using standardized items, including the AUDIT-C [163] for
alcohol, the 5A’s for smoking [164], and the Short
Inventory of Problems—Modified for Drug Use (SIP-DU)
[165], the Drug Abuse Screening Test (DAST) [166], or a
single question screen [167] for drug use. Drug use should
include assessment of the non-medical use of controlled
substances.
8.3 Assess and Rank Each Medication According
to Risks and Benefits
Benefits and risks from each medication can be assessed
based on standardized instruments, clinical judgment, and
the general and HIV literature. Several groups have devel-
oped and piloted tools to identify under- and overprescribing
for the general medical patient. The Medication Appropri-
ateness Index relies on implicit criteria to identify the over-
use of an individual medication based on the indication,
effectiveness, dosage, implementation, duration, and cost
[168]. Explicit criteria, generally based on expert consensus,
Table 1 Impact of substance use on ART
Substance Metabolism [123, 149, 151, 152] Clinical effect of substance–ART interactions




Amphetamines Liver metabolism: aromatic hydroxylation;
N-dealkylation; deamination; CYP2D6,
CYP2B6, CYP1A2, CYP3A4
Protease inhibitors inhibit CYP3A4 and ritonavir,
nelfinavir, and efavirenz inhibit CYP2B6, potentially
leading to increased levels of amphetamines;
Fatal interaction has been reported with ritonavir
Decreases [115,
162]
Cannabis CYP3A4, CYP2C9 substrate; smoking induces
CYP1A2
Protease inhibitors may increase risk of marijuana
toxicity;
No evidence of clinical impact on ART metabolism
Decreases [148,
150]
Cocaine Spontaneous hydrolysis; hepatic
cholinesterases; CYP 3A4 substrate; inhibits
CYP2D6 (strong); CYP3A4 (weak)
Increases P-glycoprotein levels
Limited evidence, but could theoretically increase
excretion of ARTs transported by p-glycoprotein





Ethanol Alcohol dehydrogenase, aldehyde
dehydrogenase
No clinically significant interactions with ARTs Decreases [156,
157]
Opioids Hepatic esterases (heroin)
Glucuronidation (codeine, morphine)
CYP3A4, 2D6 (semisynthetic opioids,
i.e., hydrocodone, oxycodone)
No known interactions between ART and heroin,
morphine and codeine
Oxycodone increased by CYP2D6 inhibitors (i.e.,
ritonavir); hydrocodone effects are decreased as its
metabolite, hydromorphone, is more potent, potentially
resulting in withdrawal symptoms
Decreases [156,
158]
Tobacco CYP 2A6, 1A2 None reported Mixed data
[159, 160]
CYP cytochrome P450
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have also been developed. The most commonly referenced
explicit criteria are the BEERS Criteria. First published in
1991 [140] and regularly updated since then [169–171], the
current BEERS Criteria include 53 specific medications/
medication classes to avoid in older patients. Only one of
these sets of criteria addresses both over- and underpre-
scribing: the Screening Tool of Older Persons’ Potentially
Inappropriate Prescriptions (STOPP) and Screening Tool to
Alert Doctors to Right Treatment (START) criteria [139].
These include 65 indicators, which are mainly focused on
drug–drug and drug–disease interactions and therapeutic
duplication, and incorporate 22 evidence-based indicators of
prescribing omissions.
While there are generally limited data demonstrating the
use of these tools to improve clinical outcomes [86], cur-
rent evidence suggests that the STOPP/START criteria are
more sensitive than the BEERS criteria for identifying
potentially inappropriate medications [172] and patients at
risk for adverse drug events [173, 174], and that they may
be used as an intervention to promote more appropriate
prescribing [175]. Accordingly, the STOPP/START crite-
ria have been endorsed over other tools [172, 176].
The adaptation of instruments such as the STOPP/
START criteria for HIV-infected patients will require
additional investigation. For example, the START criteria
recommend statin initiation under the following circum-
stances: (1) diabetes mellitus if one or more co-existing
major cardiovascular risk factor is present; and (2) a doc-
umented history of coronary, cerebral, or peripheral vas-
cular disease, where the patient’s functional status remains
independent for activities of daily living and life expec-
tancy is [5 years, with the specification that simvastatin
40 mg is typically the treatment of choice and that dose
and choice should no longer be based on a target choles-
terol except in diabetes [177]. Since HIV-infected patients
have an increased risk of cardiovascular disease [178], and
statins may have additional benefits in HIV-infected pop-
ulations through their impact on inflammation [179], there
may be expanded indications for statin therapy among
HIV-infected patients. However, such recommendations
need to balance the risks of polypharmacy [94], and should
be tailored to minimize drug–drug interactions and opti-
mize effectiveness [180]. Specifically, simvastatin and
lovastatin are not recommended for those on protease
inhibitors [22].
In addition, while the STOPP criteria indicate that long-
term opiates should be stopped in those with recurrent falls
and those with dementia unless indicated for palliative care
or management of moderate-to-severe chronic pain syn-
drome, there may be additional indications for altering
prescribing for HIV-infected patients. The potential bene-
fits from pain relief should be weighed against the risk of
developing opioid abuse and dependence [181–184], as
well as other opioid side effects, including the potential for
impaired immune function [185], system-level toxicities
[186, 187] and interactions with medications, including
ART [149, 151].
Risk can be assessed based on past medical history of
ADEs, substance use, number of medications, and overall
burden of disease. Given their role in drug metabolism and
the high prevalence of disease in HIV-infected patients,
liver, kidney, and bone marrow function should be care-
fully assessed with validated measures, such as those
included in the VACS Index (http://vacs.med.yale.edu).
Initially developed for HIV-infected patients, the VACS
Index combines age with routinely ordered labs (HIV-1
RNA viral load, CD4 count, hemoglobin, platelets, aspar-
tate and alanine transaminase, creatinine, and HCV serol-
ogy) to predict all-cause mortality. In addition to mortality,
the VACS Index predicts hospitalization and intensive care
unit admission, and is correlated with functional perfor-
mance, fragility fractures, and quality of life [19, 20, 82,
83, 102, 104, 105, 188, 189]. The VACS Index is also
sensitive to changes in ART [85]. Patients at a higher risk
of all-cause mortality based upon the VACS Index are
likely at a greater risk of ADE due to their decreased organ
system reserve and heightened risk of both short- and long-
term mortality. While it holds promise as a potentially
effective tool for guiding clinical decisions, randomized
controlled trials are needed to evaluate whether the VACS
Index prevents inappropriate prescribing.
8.4 Prioritize and Plan with the Patient
Prioritized ranking of medications should be informed by
patient preferences including disease-specific benefit harm
thresholds and the relative utility of individual drugs. ART
will typically be ranked as most beneficial. Medications that
decrease heavy drinking, such as naltrexone, or that treat
opioid dependence, including methadone and buprenor-
phine, may improve adherence to ART and quality of care
and might therefore take precedence over other types of
medication [190, 191]. When available, comparative
effectiveness data among those with HIV should guide
medication choices. Similarly, the risk/benefit ratio of
medications when used specifically in HIV-infected
patients should be considered before initiating them. For
example, Womack and colleagues found that, specifically
among HIV-infected patients, proton pump inhibitors are
associated with a 55% increased risk of fracture
(HR = 1.55 [95 % CI 1.28, 1.89]) [77]. Given the increased
prevalence of bone disease among HIV-infected patients
[78, 192], the common use of PPIs [43, 77] is especially
concerning for older, HIV-infected patients. Also consider
whether medications (other than ART) that have been
poorly adhered to are associated with unwelcome symptoms
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and should be discontinued. Finally, increasingly tough
criteria should be used for the continuation of medications
ranked lower than 5th, 7th, or 10th on the priority list, since
risk of harm increases substantially with these thresholds
[32–34]. Nonprescription alternatives, including behavioral
interventions and prevention counseling, should be con-
sidered and utilized when appropriate [15]. Further, medi-
cations such as bisphosphonates may not be indicated for
osteoporosis prevention if only short-term survival is
expected based upon the VACS Index.
In collaboration with patients, providers should deter-
mine which medications will be stopped and which ones
started, how medication effectiveness will be monitored for
therapeutic and adverse effects, and when additional
changes might be considered. Techniques for improving
adherence to high-priority medications beyond simply
stopping other medications should be reviewed. Methods
for deciding when to start or stop medications ought to be
established with the initiation of new medications. Impor-
tantly, by incorporating patient preferences and jointly
ranking medications, providers may improve the patient’s
ability and willingness to adhere to high-priority medica-
tions and the completeness with which they report their
total medication list to their provider.
8.5 Role of Clinical Decision Support Systems
Only one study reviewed by the Cochrane Collaboration
used a computerized clinical decision support (CDS)
intervention, but it decreased inappropriate and increased
appropriate polypharmacy [1]. Healthcare clinics and sys-
tems that have access to computerized pharmacy dispens-
ing records have a clear advantage in that these could be
used as an excellent starting point for generating a list of
medications and level of adherence. However, providers
should be careful to ascertain and record medication
obtained outside and to develop standard methods to
include this documentation within the database. This
practice is now routine within the VA Healthcare System.
CDS could also be used to estimate risk of ADR and
mortality by calculating the VACS Index based upon
routine laboratory values and to screen for likely drug–drug
interactions (so long as the electronic pharmacy list is
complete and accurate). An excellent example of an
effective CDS in the management of individuals aging with
HIV is that by Robbins et al. [143].
9 Conclusions and Future Directions
In the same way that HIV providers are less comfortable
with general medicine [136], primary care providers are less
knowledgeable about HIV [193]. In the era of cART success
and the management of HIV infection as a chronic disease,
integrated systems of care, including HIV specialists, pri-
mary care and clinical pharmacists [194], and integrated
information systems facilitating excellent communication
will be essential for optimizing the care of older, HIV-
infected patients [137, 138]. Given the changing face of the
HIV epidemic, providers will be increasingly challenged to
effectively manage older, HIV-infected patients with mul-
timorbidity. Future research efforts should focus on deter-
mining the safety and efficacy of cART regimens in older
patients and their long-tem effects, and address the larger
issue of polypharmacy considering both HIV and non-HIV
medications. Strategies to optimize appropriate polyphar-
macy for HIV-infected patients need to be adapted from
prior work outside HIV and evaluated among those aging
with HIV. A critical component will include risk assess-
ment, such as that offered by the VACS Index, to inform the
prioritization of medications according to their risks and
benefits for each patient. In addition, efforts to promote
public health initiatives, behavior change, and prevention
aimed at reducing polypharmacy should be investigated.
Finally, the efforts to tailor polypharmacy interventions to
those aging with HIV may provide an important template for
adapting these interventions to other complex chronic dis-
eases in which there is a ‘‘primary condition’’ which takes
precedence, as would be true of many forms of cancer or
severe diabetes. Investigations of the transportability of such
approaches to different settings, including to non-Western
countries, are needed.
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